Posted by Michael Wonder on 30 Jul 2020
Proposal to fund an additional brand of budesonide with eformoterol
30 July 2020 - PHARMAC is seeking feedback on a proposal to fund an additional brand (DuoResp Spiromax) of two of the three funded strengths of budesonide with eformoterol dry powder inhaler from 1 October 2020 through a provisional agreement with Teva Pharmaceuticals.
There would be no changes to the currently funded brands of budesonide with eformoterol dry powder inhalers (Symbicort Turbuhaler) and aerosol inhalers (Vannair).
Budesonide with eformoterol inhalers are used for the treatment of asthma and chronic obstructive pulmonary disease.
